gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · MGNXHealthcarePharmaceuticals

MacroGenics, Inc. (MGNX)

$2.30−1.50%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.29▲ 45.25% in range
Nov 3, 2025Low $1.33 · High $4.86Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

MacroGenics closed at $2.29 on Nov 4, down 1.50%, 52.8% below its 52-week closing high. Volume of 586.8K shares was 0.60× its 20-day average (below normal).

Split-adjusted performance: -37.0% over one month, -23.8% over six months, +45.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $32.83M, up 378.0% from a year earlier, with a net margin of 59.4%.

Short interest was 5.1M shares at the Oct 15 settlement, down 28.1% from the prior report (8.2% of float, 8.2 days to cover).

Market cap$146.2M63.7M shares
Revenue · quarter$32.8M+378.0% YoY
Diluted EPS$0.31—
P/E · TTM—P/S 0.9×
Net margin59.4%Gross 100.0%
Dividend yieldNone
52-week range1.33 – 4.86−52.8% from high
Volume586.8K0.60× 20-day avg
Volatility · 60d113.6%Annualised
Short % of float8.2%8.2 days to cover
Net cash$173.3MCash $173.3M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.1%1M −37.0%3M −42.8%6M −23.8%YTD +42.5%1Y +45.3%3Y −55.5%5Y −88.3%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum52
Revenue growth93
Net margin95
Value (low P/E)—
Size45

Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short5.1M−28.1% vs prior
Days to cover8.2Settled Oct 15
% of float8.2%
Short vol. 10d46.9%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
MGNXMacroGenics$2.30−1.50%−23.8%+378.0%59.4%—$146.2M
RNAAtrium Therapeutics$8.66−0.69%−33.8%−21.9%−672.0%—$148.1MCompare
CUECue Biopharma$18.92−9.30%−44.3%+166.7%−1943.2%—$137.4MCompare
ANTXAN2 Therapeutics$4.17−0.24%−10.3%———$157.4MCompare
DERMJourney Medical$4.80+3.45%−7.9%+18.9%−1.7%—$135.5MCompare
PYXSPyxis Oncology$1.62−1.52%−29.8%−100.0%——$134.7MCompare
FHTXFoghorn Therapeutics$2.22+3.99%−52.7%+112.7%−44.7%—$131.5MCompare
YARWYarrow Bioscience$15.53−15.46%————$131.1MCompare
SPRBSpruce Biosciences$45.26+5.72%−21.8%———$130.1MCompare

News about MacroGenics

All news →
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?Zacks Investment Research · Oct 9, 2026▲ PositiveMacroGenics to Participate in Upcoming Investor ConferencesGlobeNewswire Inc. · Feb 26, 2026Neutral

Quick answers

What does MacroGenics do?
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules).
What is MGNX's market cap?
$146.19M, based on the Nov 4 close of $2.29.
Does MacroGenics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of MGNX is sold short?
5.1M shares, 8.2% of float, as of Oct 15, 2026.
What sector is MGNX in?
Healthcare, in the Pharmaceuticals industry.

About MacroGenics

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

HQ: Rockville, MD293 employeesListed Oct 10, 2013macrogenics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology